Breaking News Instant updates and real-time market news.

ASND

Ascendis Pharma

$114.89

0.62 (0.54%)

, HARP

Harpoon Therapeutics

$11.48

0.1 (0.88%)

04:55
08/14/19
08/14
04:55
08/14/19
04:55

Wedbush to hold a conference

Wedbush PacGrow Healthcare Conference will be held in New York on August 13-14.

ASND

Ascendis Pharma

$114.89

0.62 (0.54%)

HARP

Harpoon Therapeutics

$11.48

0.1 (0.88%)

XNCR

Xencor

$38.70

1.23 (3.28%)

UTHR

United Therapeutics

$80.18

-0.95 (-1.17%)

RCUS

Arcus Biosciences

$7.41

0.34 (4.81%)

GTHX

G1 Therapeutics

$37.35

5.86 (18.61%)

TCRR

TCR2 Therapeutics

$15.16

-0.95 (-5.90%)

VYGR

Voyager Therapeutics

$20.54

0.46 (2.29%)

NVCR

Novocure

$88.72

2 (2.31%)

MLND

Millendo Therapeutics

$7.10

-0.21 (-2.87%)

BOLD

Audentes Therapeutics

$34.07

0.48 (1.43%)

SGMO

Sangamo

$11.45

0.2 (1.78%)

  • 14

    Aug

  • 15

    Aug

  • 04

    Sep

  • 04

    Sep

  • 09

    Sep

  • 11

    Sep

  • 12

    Sep

ASND Ascendis Pharma
$114.89

0.62 (0.54%)

06/26/19
JPMS
06/26/19
NO CHANGE
JPMS
Overweight
Ascendis Pharma share weakness an overreaction, says JPMorgan
JPMorgan analyst Jessica Fye noted that shares of Overweight-rated Ascendis Pharma are weak today on additional IGF-1 SDS details from fliGHt and heiGHt. In a research note to investors, Fye says she views the stock move as an overreaction and would buy shares on weakness with a company that she sees as possessing a de-risked platform and not only a portfolio of orphan endocrine assets but also an emerging oncology pipeline with its first IND set for 2020.
06/28/19
WELS
06/28/19
NO CHANGE
WELS
Outperform
Ascendis Pharma recent pullback a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough views the recent weakness in shares of Ascendis Pharma as a buying opportunity. After speaking with management, the analyst has increased confidence in the superior tolerability and efficacy of TransCon human growth hormone versus daily growth hormone and its opportunity in the $3B-plus market. He keeps an Outperform rating on Ascendis with a $176 price target.
06/26/19
CANT
06/26/19
NO CHANGE
Target $185
CANT
Overweight
Ascendis Pharma weakness amid R&D day overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young noted that shares of Ascendis Pharma have been weak this morning as the company holds an R&D day. Her view is the that company's "extensive 212-page slide deck" shares some new analysis around heiGHt and more detailed info on fliGHt after top-line data in Q2. She sees the current stock weakness as overblown and thinks the profile of TransCon hGH remains consistent. Young reiterated her Overweight rating and $185 price target on Ascendis shares, which are down 7% to $112.18 in early afternoon trading.
07/18/19
JPMS
07/18/19
NO CHANGE
JPMS
Overweight
Ascendis Pharma has $2B commercial opportunity, says JPMorgan
JPMorgan analyst Jessica Fye left a call with a pediatric endocrinologist "even more convinced" that the IGF-1 concerns around TransCon growth hormone are overblown and that the existing daily growth hormone market should "convert rapidly" to long acting with Ascendis Pharma "taking the greatest share." The analyst sees a $2B commercial opportunity for the company and keeps an Overweight rating on the shares.
HARP Harpoon Therapeutics
$11.48

0.1 (0.88%)

04/22/19
BARD
04/22/19
INITIATION
Target $25
BARD
Outperform
Harpoon Therapeutics initiated with an Outperform at Baird
Baird analyst Michael Ulz started Harpoon Therapeutics with an Outperform rating and $25 price target.
03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord initiated Harpoon Therapeutics with a Buy and $24 price target.
03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Harpoon Therapeutics with a Buy as she sees solid prospects for it lead drug candidate TriTac, which engages T cells to harness the body's immune system to treat cancer and other diseases. Lee has a $24 price target on Harpoon Therapeutics shares.
05/24/19
SBSH
05/24/19
INITIATION
Target $23
SBSH
Buy
Harpoon Therapeutics assumed with a Buy at Citi
Citi analyst Yigal Nochomovitz assumed coverage of Harpoon Therapeutics with a Buy rating and lowered his price target for the shares to $23 from $25. The analyst sees potential for upside over the next 12 months from initial clinical data from lead drug HPN424 in prostate cancer and HPN536 in mesothelin positive cancers.
XNCR Xencor
$38.70

1.23 (3.28%)

08/07/19
GUGG
08/07/19
DOWNGRADE
GUGG
Neutral
Xencor downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Xencor to Neutral from Buy saying he's looking for a more attractive entry point.
08/08/19
ADAM
08/08/19
NO CHANGE
Target $52
ADAM
Buy
Xencor price target raised to $52 from $45 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $52 from $45 citing its commercial product Xtend which is already generating sales, multiple partnered programs, and wholly owned programs progressing through the clinic. Lee reiterated her Buy rating on Xencor shares.
08/07/19
WEDB
08/07/19
NO CHANGE
Target $54
WEDB
Outperform
Xencor price target raised to $54 from $43 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Xencor (XNCR) to $54 from $43 as he believes it remains a de-risked platform name, no near-term cash needs, and with support for its valuation from Alexion (ALXN) Ultomiris royalties, and a potentially more significant royalty stream from tafasitamab with multiple early-stage pipeline candidates to provide future upside. The analyst reiterates an Outperform rating on Xencor's shares.
08/08/19
CANT
08/08/19
NO CHANGE
Target $40
CANT
Overweight
Xencor post earnings selloff yesterday overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young views the post-earnings selloff yesterday in shares of Xencor as overdone. While the company shifted timelines for SSTR2xCD3 and PD-1xCTLA-4 assets from end of 2019 to the first half of 2020, the selloff yesterday was likely an overreaction, Young tells investors in a research note. She thinks Xencor's platform value remains the same and views the company as very well capitalized with $625M in cash. The analyst reiterates an Overweight rating on the shares with a $40 price target.
UTHR United Therapeutics
$80.18

-0.95 (-1.17%)

08/01/19
LTCO
08/01/19
UPGRADE
Target $106
LTCO
Buy
United Therapeutics upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan upgraded United Therapeutics to Buy from Neutral and raised his price target for the shares to $106 from $103. The analyst is encouraged by the product sales reported by the company in Q2. He expects United Therapeutics to continue to maintain a "significant" market share in pulmonary hypertension with Remodulin due to practitioner preference. The company will be able to maintain a "relatively steady" revenue base and potentially continue to grow revenues as its pipeline advances to replace their genericized products, Kaplan tells investors in a research note.
07/01/19
07/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anaplan (PLAN) upgraded to Buy from Neutral at Goldman Sachs with analyst Heather Bellini saying the company's deal sizes are growing and the pace of its expansions are increasing as sales productivity improves. 2. Six Flags (SIX) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress citing an improving near-term setup, led by his Key First Look data supporting above-consensus attendance trends for Q2, meaningfully easier Q3 weather compares, and a de-risked international scenario, all against what he believes is a rock-bottom level of sentiment around the name. 3. Western Digital (WDC) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying he believes the Huawei ban has been a "major overhang" for handset radio frequency suppliers Qorvo (QRVO) and Skyworks (SWKS), and memory suppliers like Western Digital. 4. Valvoline (VVV) upgraded to Buy from Neutral at Buckingham. 5. United Therapeutics (UTHR) upgraded to Outperform from Neutral at Credit Suisse with analyst Martin Auster saying he sees downside as limited with multiple attributes that could support near-term stabilization/rebound, including potential for less aggressive generic uptake, greater recognition of steady Tyvaso/Orenitram cash flows with potential for strong Tyvaso tail value, ralinepag's potential best-in-class profile, potential for share buybacks, and potential for activism/M&A. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/19
08/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Spotify (SPOT) upgraded to Hold from Sell at Loop Capital with analyst Alan Gould saying the company's Q2 marked "another good quarter" as it reached renewal deals with 2 of 4 major labels for global recording. 2. Crown Castle (CCI) upgraded to Overweight from Neutral at JPMorgan. 3. Vanda Pharmaceuticals (VNDA) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying the current stock price is undervaluing Vanda's "profitable" base business due to "very poor" investor sentiment related to pipeline agent tradipitant. 4. United Therapeutics (UTHR) upgraded to Hold from Underperform at Jefferies with analyst Eun Yang citing valuation. 5. Five9 (FIVN) upgraded to Overweight from Neutral at JPMorgan and to Buy from Neutral at Dougherty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/19
JEFF
08/01/19
UPGRADE
Target $90
JEFF
Hold
United Therapeutics upgraded to Hold from Underperform at Jefferies
Jefferies analyst Eun Yang upgraded United Therapeutics to Hold from Underperform with an unchanged price target of $90. The analyst cites valuation for the upgrade after the company reported higher Q2 revenue and lower operating expenses.
RCUS Arcus Biosciences
$7.41

0.34 (4.81%)

03/18/19
BTIG
03/18/19
INITIATION
Target $20
BTIG
Buy
Arcus Biosciences initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Arcus Biosciences with a Buy rating and a price target of $20, citing the company's work in chemotherapy and its focus on "driving antitumor immune responses beyond the level achievable by immune checkpoint inhibitors." The analyst sees its data released thus far as "compelling" and notes "several trials" currently enrolling with data expected in mid-2019, with results that could potentially "establish proof of biology and validate patient selection biomarkers." Shrader further notes that Arcus Biosciences' $260M in cash "gives the company runway to optimize its long-term strategy."
06/05/19
SBSH
06/05/19
NO CHANGE
Target $15
SBSH
Buy
Arcus Biosciences price target lowered to $15 from $25 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Arcus Biosciences to $15 from $25 saying the Phase I data for the company's AB928 and AB122 combo in advanced solid tumors were "somewhat underwhelming." An 11% overall response rate is only in-line with other efforts targeting the adenosine pathway, Nochomovitz tells investors in a research note. He believes the data raise the risk that Arcus will succeed in showing a differentiated profile. Nonetheless, the analyst keeps a Buy rating on the shares.
03/18/19
03/18/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Western Asset Mortgage (WMC) initiated with a Market Perform at Keefe Bruyette. 2. Cars.com (CARS) initiated with a Neutral at Goldman Sachs. 3. Super League Gaming (SLGG) initiated with an Outperform at Northland. 4. Arcus Biosciences (RCUS) initiated with a Buy at BTIG, while Momenta (MNTA) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
SBSH
05/24/19
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences assumed with a Buy at Citi
Citi analyst Yigal Nochomovitz assumed coverage of Arcus Biosciences with a Buy rating and $25 price target. The analyst sees an attractive risk/reward profile ahead of clinical data from the company's chemo/PD-1 combo trials in multiple cancers with lead compound AB928 in mid and the second half of 209. He sees potential for 5%-10% upside from each of three key data events expected in 2019.
GTHX G1 Therapeutics
$37.35

5.86 (18.61%)

02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
B. Riley FBR starts G1 Therapeutics with Buy rating, $55 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. G1's lead candidate, trilaciclib, has the potential to address myelotoxicity and improve overall survival in chemotherapy-associated treatment regimens, Polishetty tells investors in a research note. Further, Lerociclib, although fourth to market, demonstrates potential to be best in class given its clean safety profile thus far adds the analyst. She also believes G1T48 allows for competitive pricing when both lerociclib and G1T48 hit the market.
08/08/19
JPMS
08/08/19
UPGRADE
Target $45
JPMS
Overweight
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded G1 Therapeutics to Overweight from Neutral and raised his price target for the shares to $45 from $38. The analyst sees a "string of important key catalysts" in the second half of 2019 and first half of 2020 for G1's pipeline. Rama now includes G1T48 in his model with initial phase 1 data in ER+/HER2- breast cancer coming at the end of September. Further, at current share levels, the analyst believes limited value is being ascribed to lerociclib.
06/18/19
HCWC
06/18/19
NO CHANGE
HCWC
G1 Therapeutics trial results 'important,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $71 price target on G1 Therapeutics. The analyst noted that G1 Therapeutics' topline OS improvements from its randomized, open-label Phase 2 trial evaluating trilaciclib in metastatic triple-negative breast cancer were "statistically significant in both treatment arms compared with the control arm." White believes that "an OS benefit seen in a small three-arm trial like this is an important result" and added that "the company can now pursue an efficacy benefit as well as the myelopreservation pathway... for commercialization."
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
G1 Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started G1 Therapeutics with a Buy rating and $55 price target.
TCRR TCR2 Therapeutics
$15.16

-0.95 (-5.90%)

05/31/19
ROTH
05/31/19
INITIATION
Target $16
ROTH
Neutral
TCR2 Therapeutics initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler started TCR2 Therapeutics with a Neutral rating and $16 price target, telling investors that he finds the company's proprietary TCR Fusion-Construct Tcells, or TRuC-T cells, platform promising, but that its clinical programs are "too early to call."
03/11/19
03/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TCR2 Therapeutics (TCRR) initiated with an Outperform at SVB Leerink, Wedbush, and BMO Capital, while being initiated with a Buy at Jefferies. 2. Barings BDC (BBDC) resumed with an Outperform at Wells Fargo. 3. Avedro (AVDR) initiated with an Overweight at JPMorgan while being initiated with an Outperform at SVB Leerink and Cowen. 4. Anchiano Therapeutics (ANCN) initiated with a Buy at Ladenburg and an Outperform at Oppenheimer. 5. CytomX Therapeutics (CTMX) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/11/19
LEER
03/11/19
INITIATION
Target $27
LEER
Outperform
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
SVB Leerink analyst Jonathan Chang initiated TCR2 Therapeutics with an Outperform rating and $27 price target. In a research note to investors, Chang says he has received positive feedback from MEDACorp Key Opinion Leaders on the company's T-Cell Receptor Fusion Construct pipeline based on the preclinical data to date that highlights the potential of TCR2's approach. The analyst maintains a positive long-term view of the stock based on the experienced management team and potentially transformative platform with broad therapeutic applicability.
03/11/19
JEFF
03/11/19
INITIATION
Target $31
JEFF
Buy
Jefferies starts TCR2 Therapeutics with Buy rating, $31 price target
Jefferies analyst Biren Amin initiated coverage of TCR2 Therapeutics with a Buy rating and $31 price target. The company is developing a "broad pipeline" centered on its TRuC technology that endows certain advantageous properties to T-cells for targeting solid tumors, where CAR-Ts have not seen much success, Amin tells investors in a research note. While early in development, the analyst believes TCR2 may offer a differentiated approach.
VYGR Voyager Therapeutics
$20.54

0.46 (2.29%)

05/08/19
HCWC
05/08/19
NO CHANGE
Target $26
HCWC
Buy
Voyager Therapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Voyager Therapeutics to $26 from $22 saying execution was the consistent theme during the company's Q1 results. The analyst sees a "solid" balance sheet and "compelling" partnerships. He keeps a Buy rating on the shares.
06/18/19
WEDB
06/18/19
NO CHANGE
Target $36
WEDB
Outperform
Voyager Therapeutics price target raised to $36 from $27 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Voyager Therapeutics to $36 from $27 as we begin to incorporate Huntington's disease gene therapy candidate VY-HTT01 into his valuation, assigning it a preliminary program valuation of about $9.5/share. The analyst reiterates an Outperform rating on the shares.
06/20/19
NOMU
06/20/19
NO CHANGE
Target $37
NOMU
Buy
Voyager Therapeutics price target raised to $37 from $26 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Voyager Therapeutics (VYGR) to $37 from $26 after the company announced a restructured deal with Sanofi (SNY). Voyager now has worldwide rights to VY-HTT01 for Huntington's disease, and the ex-U.S. rights to VYFXN01 for Friedreich's ataxia have now been transferred to Neurocrine (NBIX), Marai tells investors in a research note. He believes obtaining the full rights to HTT01 is a positive for Voyager, especially after Roche (RHHBY) "posted positive derisking data." Marai reiterates a Buy rating on Voyager Therapeutics.
07/12/19
MSCO
07/12/19
NO CHANGE
Target $28
MSCO
Equal Weight
Voyager Therapeutics price target raised to $28 from $21 at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung raised his price target on Voyager Therapeutics (VYGR) shares to $28 from $21 after the company recently announced that it will be getting back rights to VY-HTT01 for Huntington's disease in a restructuring of its partnership with Sanofi Genzyme (SNY). While early in development, Hungs think VY-HTT01 could be a roughly $900M product for Voyager. Although he appreciates the opportunity in Huntington's and is "constructive" on VY-AADC in Parkinson's, Hung keeps an Equal Weight rating on Voyager shares, citing what he sees as limited near-term clinical catalysts.
NVCR Novocure
$88.72

2 (2.31%)

07/26/19
WEDB
07/26/19
DOWNGRADE
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
07/26/19
WEDB
07/26/19
DOWNGRADE
Target $80
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Novocure to Neutral from Outperform, telling he believes shares are now fully valued at the current levels following its recent performance. The analyst raised his price target to $80 from $57 to reflect current positive glioblastoma adoption trends, and notes that longer-term, positive results from clinical trials in new indications could give revenues a new growth trajectory beyond the underlying core GBM franchise. Nierengarten advises investors to wait for a more attractive entry point, as risks outweigh the rewards at these levels.
07/29/19
RHCO
07/29/19
UPGRADE
Target $105
RHCO
Buy
Novocure upgraded to Buy from Hold at SunTrust
SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48.
07/29/19
07/29/19
UPGRADE
Target $105

Buy
Novocure upgraded to Buy from Hold at SunTrust
As previously reported, SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48. The analyst says that he has long recognized the stock as an "under-the-radar" oncology investment story that calls for investor attention, but notes that the interest and excitement about Optune's potential in future indications is growing. Gilbert notes that his updated model now includes "probability adjusted" sales for Phase 3 indications with some areas of "potential conservatism".
MLND Millendo Therapeutics
$7.10

-0.21 (-2.87%)

07/15/19
OPCO
07/15/19
INITIATION
Target $26
OPCO
Outperform
Millendo Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Millendo Therapeutics with an Outperform rating and $26 price target, citing his view on the company's drugs in development for Prader Willi Syndrome, Congenital Adrenal Hyperplasia and Cushing's Syndrome. He is "impressed" with the early efficacy data for livoletide and nevanimibe, which show "reasonably clean" safety and tolerability, and sees Millendo as a leader in orphan endocrine diseases, Olson tells investors.
07/18/19
WEDB
07/18/19
INITIATION
Target $24
WEDB
Outperform
Millendo Therapeutics initiated with an Outperform at Wedbush
Wedbush initiated Millendo Therapeutics with an Outperform rating and $24 price target.
07/19/19
WEDB
07/19/19
INITIATION
Target $24
WEDB
Outperform
Millendo Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated Millendo Therapeutics with an Outperform rating and $24 price target. In a research note to investors, Chico notes that the company's lead asset livoletide is in a registrational study for the treatment of Prader-Willi syndrome, which affects roughly 10,000 patients in the U.S. Data from the ZEPHYR study is set to arrive in the first half of 2020, and, with additional data coming for Millendo's nevanimibe, expects Millendo to approach an important value-creating period. While shares have come under recent pressure since June, Chico says she sees favorable risk/reward with cash offering limited downside protection, and livoletide success helping shares work towards the $24 price target.
03/13/19
JEFF
03/13/19
INITIATION
Target $22
JEFF
Buy
Millendo Therapeutics initiated with a Buy at Jefferies
Jefferies analyst David Hoang started Millendo Therapeutics with a Buy rating and $22 price target. The company is developing livoletide for Prader Willi syndrome and nevanimibe for congenital adrenal hyperplasia, Hoang tells investors in a research note. He believes the Street is giving little credit to these orphan diseases despite positive Phase IIa data and "sizable" revenue opportunities. The analyst says Millendo's risk/reward looks skewed to the upside.
BOLD Audentes Therapeutics
$34.07

0.48 (1.43%)

04/17/19
LEER
04/17/19
NO CHANGE
Target $48
LEER
Outperform
Audentes Therapeutics price target raised to $48 from $37 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Audentes Therapeutics to $48 from $37, while reiterating an Outperform rating on the shares. The analyst notes that the company has expanded its pipeline to include Pompe disease and more recently, Duchenne muscular dystrophy and myotonic dystrophy.
04/26/19
SBSH
04/26/19
DOWNGRADE
SBSH
Sell
Audentes Therapeutics downgraded to Sell from Neutral at Citi
04/26/19
HCWC
04/26/19
NO CHANGE
Target $48
HCWC
Buy
Audentes Therapeutics price target raised to $48 from $44 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Audentes Therapeutics to $48 from $44 saying the company is delivering on its pipeline expansion. He keeps a Buy rating on the shares.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $55
PIPR
Overweight
Piper Jaffray bullish on Audentes Therapeutics after AT132 update
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $32 price target on Audentes Therapeutics following a "positive" update for AT132 at ASGCT. Clinical benefit continues to be demonstrated in all patients in Cohort 1 with additional improvements across measures with now four patients ventilator independent and further improvement in muscle biopsies observed, he notes, adding that patients in Cohort 2 demonstrated accelerated pathological recovery in muscle biopsy samples at 24 weeks, with additional benefits highlighted in neuromuscular function and reductions in ventilator dependence.
SGMO Sangamo
$11.45

0.2 (1.78%)

07/26/19
ADAM
07/26/19
NO CHANGE
Target $37
ADAM
Buy
Homology Medicines selloff yesterday a buying opportunity, says Canaccord
Canaccord Genuity analyst Michelle Gilson attributes the selloff yesterday in shares of Homology Medicines (FIXX) to a pre-printed, and not peer-reviewed, paper that did not support the company's in vitro data around HR-mediated gene editing. The paper's author, who has previously worked with Sangamo Therapeutics (SGMO) on ZFN-mediated editing, was unable to induce homologous recombination without a nuclease, Gilson tells investors in a research note. "It is tough to understand why an author would choose this route of publication for a study of this nature," says the analyst. She sees "several key differences" between the author's and Homology's in vitro experiments. Further, Homology's technology has been externally validated, allowing Novartis (NVS) and other labs to perform their own in-house experiments using Homology plasmids, Gilson contends. She adds that following this validation, Novartis entered into a collaboration specifically revolving around Homology's gene editing technology for ophthalmic targets. The analyst keeps a Buy rating on Homology Medicines with a $37 price target. Gilson views the selloff in the shares as a buying opportunity into the Phase 1/2 pheNIX data by the end of 2019 for HMI-102 gene therapy in phenylketonuria.
07/08/19
PIPR
07/08/19
NO CHANGE
PIPR
Overweight
BioMarin's Valrox maintains competitive advantage, says Piper Jaffray
After BioMarin (BMRN) announced that the company will submit regulatory filings for Valrox to both the FDA and EMA in Q4, and after the company and competitive partners Sangamo (SGMO) and Pfizer (PFE) both presented updates at this weekend's International Society on Thrombosis and Hemostasis meeting, Piper Jaffray analyst Christopher Raymond said that he still believes the company's roughly 2-year head start puts Valrox at a competitive advantage. Following the confirmation on timing for accelerated filing, Raymond said he would continue to be a buyer of BioMarin shares and he keeps an Overweight rating on the stock.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.
07/12/19
JEFF
07/12/19
NO CHANGE
Target $19
JEFF
Buy
Sangamo should be bought at current share levels, says Jefferies
Jefferies analyst Maury Raycroft attributes the recent weakness in shares of Sangamo Therapeutics (SGMO) to negative sentiment related to BioMarin's (BMRN) valrox's durability. The market may be assuming all hemophilia A gene therapies are the same, Raycroft tells investors in a research note. However, he believes Sangamo's SB-525 could be "best-in-class" and keeps a Buy rating on the shares with a $19 price target. The analyst recommends buying the stock at current levels for the company's hemophilia A opportunity and "robust" pipeline.

TODAY'S FREE FLY STORIES

FB

Facebook

$184.70

-1.52 (-0.82%)

13:22
08/20/19
08/20
13:22
08/20/19
13:22
Periodicals
EU investigating Facebook's Libra on competition concerns, Bloomberg says »

EU antitrust regulators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

SABR

Sabre

$23.78

-0.15 (-0.63%)

13:21
08/20/19
08/20
13:21
08/20/19
13:21
Periodicals
Breaking Periodicals news story on Sabre »

DOJ files lawsuit to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$106.91

(0.00%)

13:19
08/20/19
08/20
13:19
08/20/19
13:19
Periodicals
Researchers find unpatchable security flaw in Xilinx SoC boards, ZDNet reports »

Security researchers have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/20/19
08/20
13:17
08/20/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$86.45

0.54 (0.63%)

13:17
08/20/19
08/20
13:17
08/20/19
13:17
Options
Ten legged spread prints in Target »

Ten legged spread prints…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/20/19
08/20
13:16
08/20/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$32.95

-1.52 (-4.41%)

13:15
08/20/19
08/20
13:15
08/20/19
13:15
Options
Momo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 05

    Sep

EBAY

eBay

$40.11

-0.27 (-0.67%)

, AMZN

Amazon.com

$1,813.15

-3.14 (-0.17%)

13:14
08/20/19
08/20
13:14
08/20/19
13:14
Periodicals
Shopify eyes move into logistics, challenging Amazon, FT says »

Shopify (SHOP) investors…

EBAY

eBay

$40.11

-0.27 (-0.67%)

AMZN

Amazon.com

$1,813.15

-3.14 (-0.17%)

SHOP

Shopify

$374.33

12.385 (3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 27

    Oct

SHOP

Shopify

$374.50

12.555 (3.47%)

13:12
08/20/19
08/20
13:12
08/20/19
13:12
Recommendations
Shopify analyst commentary  »

Guggenheim says partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

NCNA

NuCana

$6.01

-1.24 (-17.10%)

13:02
08/20/19
08/20
13:02
08/20/19
13:02
Recommendations
NuCana analyst commentary  »

NuCana trial enrollment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

MRSN

Mersana Therapeutics

$2.66

-0.05 (-1.85%)

13:00
08/20/19
08/20
13:00
08/20/19
13:00
Recommendations
Mersana Therapeutics analyst commentary  »

H.C. Wainwright says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$5.27

0.08 (1.54%)

12:57
08/20/19
08/20
12:57
08/20/19
12:57
Hot Stocks
PolarityTE granted Canadian patent related to micro-aggregate technology »

PolarityTE announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 09

    Sep

CFBI

Community First Bancshares

$10.15

(0.00%)

12:54
08/20/19
08/20
12:54
08/20/19
12:54
Hot Stocks
Community First to acquire ABB Financial for $7.50 per share »

Community First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCI

Navigant Consulting

$27.82

0.01 (0.04%)

12:53
08/20/19
08/20
12:53
08/20/19
12:53
Downgrade
Navigant Consulting rating change  »

Navigant Consulting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

12:45
08/20/19
08/20
12:45
08/20/19
12:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY dipped…

12:36
08/20/19
08/20
12:36
08/20/19
12:36
Conference/Events
Wolfe Research healthcare analysts to hold an analyst/industry webcast »

Global Pharma Analyst…

HAIN

Hain Celestial

$19.25

-2.63 (-12.02%)

, MKC

McCormick

$161.08

-7.445 (-4.42%)

12:32
08/20/19
08/20
12:32
08/20/19
12:32
On The Fly
Beyond Meat rises after JPMorgan says buy as stock 'appealing once again' »

Shares of Beyond Meat…

HAIN

Hain Celestial

$19.25

-2.63 (-12.02%)

MKC

McCormick

$161.08

-7.445 (-4.42%)

CPB

Campbell Soup

$42.95

-0.22 (-0.51%)

BYND

Beyond Meat

$154.10

9.66 (6.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 30

    Aug

  • 15

    Sep

  • 01

    Oct

NTDOY

Nintendo

$0.00

(0.00%)

, SNE

Sony

$55.85

0.14 (0.25%)

12:30
08/20/19
08/20
12:30
08/20/19
12:30
On The Fly
Game On: Sony acquires 'Spider-Man' developer Insomniac »

NEW RELEASES: Among the…

NTDOY

Nintendo

$0.00

(0.00%)

SNE

Sony

$55.85

0.14 (0.25%)

MSFT

Microsoft

$138.41

-0.02 (-0.01%)

FB

Facebook

$184.56

-1.66 (-0.89%)

EA

Electronic Arts

$92.54

1.64 (1.80%)

TTWO

Take-Two

$131.17

1.3 (1.00%)

ATVI

Activision Blizzard

$48.44

0.53 (1.11%)

GOOG

Alphabet

$1,192.07

-5.94 (-0.50%)

GOOGL

Alphabet Class A

$1,194.00

-5.94 (-0.50%)

UBSFY

Ubisoft

$0.00

(0.00%)

SLGG

Super League Gaming

$6.65

-0.09 (-1.34%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 12

    Sep

  • 15

    Sep

  • 18

    Sep

  • 24

    Sep

  • 27

    Oct

  • 13

    Nov

12:30
08/20/19
08/20
12:30
08/20/19
12:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HD

Home Depot

$217.43

9.455 (4.55%)

12:29
08/20/19
08/20
12:29
08/20/19
12:29
Recommendations
Home Depot analyst commentary at RBC Capital »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

ABCB

Ameris Bancorp

$36.48

-0.34 (-0.92%)

12:27
08/20/19
08/20
12:27
08/20/19
12:27
Conference/Events
Ameris Bancorp management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 23

    Sep

SABR

Sabre

$23.68

-0.25 (-1.04%)

12:25
08/20/19
08/20
12:25
08/20/19
12:25
Periodicals
DOJ to file suit to block Sabre acquisition of Farelogix, CNBC reports »

The Fly notes that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
08/20/19
08/20
12:25
08/20/19
12:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

LPLA

LPL Financial

$73.06

-0.35 (-0.48%)

12:17
08/20/19
08/20
12:17
08/20/19
12:17
Conference/Events
LPL Financial management to meet with William Blair »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/20/19
08/20
12:17
08/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.